Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Thomas Leth Frandsen, Jonas Abrahamsson, Birgitte Frederiksen Lausen, Kim Vettenranta, Mats Heyman, Michael Behrentz, Anders Castor, Peder Skov Wehner, Britt-marie Frost, Elisabeth Anne Wreford Andersen, Kjeld Schmiegelow

This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m2, ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.
OriginalsprogEngelsk
TidsskriftBritish Journal of Haematology
Vol/bind155
Udgave nummer2
Sider (fra-til)244-247
Antal sider4
ISSN0007-1048
DOI
StatusUdgivet - okt. 2011

ID: 38333751